Brief: Frequency Therapeutics Announces Formation Of Clinical Advisory Board For Remyelination In Multiple Sclerosis Program
19/12/2022 12:32
Dec 19 (Reuters) - Frequency Therapeutics Inc FREQ.O :
* FREQUENCY THERAPEUTICS ANNOUNCES FORMATION OF CLINICAL
ADVISORY
BOARD FOR REMYELINATION IN MULTIPLE SCLEROSIS PROGRAM
* PLANS REGULATORY FILING FOR ITS REMYELINATION PROGRAM IN
SECOND
HALF OF 2023
Source text for Eikon: ID:nBw3t872wa
Further company coverage: FREQ.O
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview